Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi, Jeffrey S. Weber, Christopher L. Corless, Katherine Zukotynski, Philip Friedlander, David E. Fisher, Adrián Mariño‐Enríquez, Marc S. Ernstoff, Jeffrey T. Yap, Mei‐Jun Zhu, Thomas F. Gajewski, Carol Beadling, Jason J. Luke, René González, Michael C. Heinrich, Steven O’Day, Anita Giobbie‐Hurder, Jonathan A. Fletcher, Frances A. Collichio, Kevin B. Kim, Donald P. Lawrence, Annick D. Van den Abbeele, George D. Demetri, Keith T. Flaherty
Abstract
Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeutic opportunities.
Topics & Concepts
ImatinibMedicineCancer researchMyeloid leukemiaCutaneous lymphoproliferative disorders researchCAR-T cell therapy researchMast cells and histamine